instruction:
Given a paragraph, generate a claim that is supported by the given paragraph. 1) The claim must contain information from within the paragraph. 2) A sentence within the paragraph can be used as a claim. 3) The claim should not have contradictions within the paragraph. 4) The claim should be at most one sentence long.
question:
Democrats on a subcommittee of the House of Representatives Committee on Oversight and Reform released a cache of internal Juul emails and other documents that committee staff described as early attempts to "enter schools and convey its messaging directly to teenage children." Juul's use of social media influencers to promote its vaping devices in the years after it launched in 2015 also came under scrutiny. James Monsees, Juul's co-founder and chief product officer, told the committee that the company's target audience from the beginning has been adult cigarette smokers. Among efforts cited in the Juul documents released were a $134,000 payment to set up a five-week "holistic health education" summer camp at a Maryland charter school, recruiting children from third through 12th grades, and offering $10,000 to schools using the company's "youth prevention and education" programs for students, including those caught using e-cigarette products. "You don't think that sounds strange at all?" Representative Katie Hill, a Democrat, asked Juul's chief administrative officer, Ashley Gould. "All of these educational efforts were intended to keep youth from using the product," Gould responded. When Juul realized how the school involvement could be perceived as negative, "we stopped the program," she said. In a statement after the hearing, Juul said the $134,000 donation was to "facilitate already-existing community outreach and youth-prevention programs," and said the company "did not have any direct interaction with the students." Several committee members said Juul's initiatives appeared similar to past efforts by the tobacco industry to reach young people under the guise of smoking prevention programs. Gould said Juul, which is 35 percent owned by Marlboro maker Altria Group Inc (MO.N), halted its program last year once it became aware of the tobacco industry's past moves. Caleb Mintz, 17, a New York city high school student, testified at a separate hearing on Wednesday that a Juul representative came to his school as part of an educational program on mental health and addiction last year. He said in an interview Thursday that students received "mixed messages" about the product, being told it was safe but not to buy it. Mintz said after the hearing that the Juul presentation seemed to be "playing to the side of teens as rebellious. When a teen is told not to do something, they're more likely to do it." Members of the committee also quizzed Gould and Monsees over the use of social media influencers to promote Juul's vaping devices. Company executives early on agreed that "younger consumers age 25 to 34 was going to be the target of our initial campaign," Monsees said. "They would be more receptive to new technology solutions," such as the Juul device. Amid an enormous uptick in teenage use of e-cigarettes in 2018 a 78% increase among high school students from 2017 to 2018, according to federal data Juul said it ended all social media advertising last fall. Juul also pulled many flavored nicotine pods, except mint, menthol and tobacco, from retail stores, which Monsees said represented more than half of the company's sales at that time.
answer:
U.S. lawmakers grill e-cigarette maker Juul over efforts targeted at schoolchildren.

question:
Health officials will conduct tests to determine whether the latest case is related to the previous seven that have been identified since March. Officials at the New Jersey school could not provide the current health status of the student. The latest case comes shortly after the U.S. Food and Drug Administration allowed the university to use an imported vaccine to help control the disease's spread. The past cases at the Ivy League school were caused by the meningococcal bacteria known as serogroup B. State law requires all Princeton students living in dormitories to receive a meningitis vaccine that protects against most strains but not the serogroup B variety, Princeton spokesman Martin Mbugua said in an email. The outbreak of serogroup B meningitis is rare but not the first of its kind in the United States, according to the Centers for Disease Control and Prevention. Bexsero, made by Swiss drugmaker Novartis AG, will be provided to all undergraduate students, graduate students who live in university housing on or off campus, and students and faculty with certain illnesses, such as sickle cell disease, Princeton officials said earlier this week. The FDA has allowed the use of the vaccine at Princeton under an Investigational New Drug application. The federal CDC considers the drug to be safe. "Everyone involved is working hard to organize a potential serogroup B meningococcal disease vaccine campaign as quickly as possible that fits into Princeton University's academic calendar," said CDC spokeswoman Sharon Hoskins. The Princeton inoculation campaign is set to be voluntary for students and is expected to begin in early December, with another event in February, according to the school's website. Federal and New Jersey state health officials have not advised visitors or students to avoid the campus, Mbugua said. Meningitis is a serious disease that is spread through coughing and exchanges of saliva, and people living in dormitories or other crowded living quarters are especially at risk. The most severe cases can result in death, hearing loss, brain damage, kidney disease or amputation of limbs. Symptoms include fever, headaches and stiff neck.
answer:
Eighth Princeton student diagnosed with meningitis.

question:
The release makes no mention of the cost of the drug in question, Tenofovir. A web search found that the cost for a month's supply of the antiviral drug averages just over $1,000. For some patients, that cost may be prohibitive. The cost is an issue of particular concern for developing countries, but it is also true that the price may be much lower for them than in the United States. Many pharmaceutical companies offer their drugs at steeply discounted rates in poorer countries to expand access to life-saving medicines. The release clearly says that 68 percent of women receiving the drug reduced their viral load while only 2 percent of the women in the control group had that success. It also says that the transmission of hepatitis B from mother to newborn dropped from 18 percent to 5 percent, an important clinical outcome. The release includes a discussion of harms. It states that "tenofovir was well tolerated; only one participant treated with tenofovir voluntarily withdrew from the study due to nausea." It also says that researchers "found no significant differences between the tenofovir-treated group and the control group with regard to fetal development and infant growth." Lastly, it calls for longer term, observational studies to confirm the safety of fetal exposure to tenofovir treatment. The release provides a good overview of the randomized, placebo-controlled trial which was undertaken to gauge the efficacy of the drug in both reducing the viral load of hepatitis-B-positive mothers and reducing the rate of transmission of the disease from mother to newborn. It offers solid, numerical evidence of both outcomes. It describes the number of patients (200 pregnant women), defined what constituted a "high" viral load, and described the approximate length of treatment. It did omit a mention of whether the trial was blinded. This release does not commit disease mongering. The release notes that the research is funded by Gilead Sciences. It should also have mentioned that a corresponding author disclosed speaking and advising fees from Gilead, according to the published study. The release is comparing the use of an antiviral drug given to pregnant women versus the normal procedure of giving both a vaccine and immune globulin. The release doesn't mention that tenofovir (marketed as Viread), the drug being tested, is already an FDA approved drug so many readers may not know that it's available. It was approved by the FDA in 2001 for HIV and in 2008 for chronic hepatitis B. The release just barely implies novelty with this statement which suggests a change in treating infected women who are pregnant: "Based on the findings, the investigators recommend that women be tested for HBV viral load at week 28 of pregnancy. Those with a high viral load should receive tenofovir treatment starting at gestational week 30 until delivery to reduce the risk of transmission to their infants." While the drug itself isn't novel, positive outcomes from a controlled trial on pregnant women carrying the virus does seem to introduce a new treatment approach. This release does not use any unjustifiable language.
answer:
Antiviral Treatment During Pregnancy Reduces Mother-to-Child Transmission of Hepatitis B